Trial Profile
A prospective, randomized, open-label, comparative trial of dideoxyinosine (ddI) versus dideoxycytidine (ddC) in HIV-infected patients who are intolerant of or who have failed zidovudine (AZT) therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Didanosine (Primary) ; Zalcitabine
- Indications HIV infections
- Focus Therapeutic Use
- 12 Oct 2005 New trial record.